[Source: Trends in Immunology, full page: (LINK). Summary, edited.]
Does Cross-Neutralization of SARS-CoV-2 Only Relate to High Pathogenic Coronaviruses?
Zhongren Ma, Pengfei Li, Aqsa Ikram, Qiuwei Pan
Reference: TREIMM 1717
To appear in: Trends in Immunology
Please cite this article as: Z. Ma, P. Li, A. Ikram, et al., Does Cross-Neutralization of SARS-CoV-2 Only Relate to High Pathogenic Coronaviruses?, Trends in Immunology (2020), https://doi.org/10.1016/j.it.2020.08.002
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
© 2020 Published by Elsevier.
*Correspondence: Q.P. (email@example.com)
Declaration of interests: All authors declare no competing interests.
Acknowledgements: The work was supported by the Ministry of Education of China for an Innovative Research Team in University grant (No. IRT_17R88; to Z.M.). Journal Pre- proof
Production of antibodies in response to viral infections constitutes an essential feature of adaptive immunity. Great efforts have been dedicated to characterize antibody responses in patients with coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. A recent article by Jiang et al, published in Trends in Immunology discussed the state of research and development of neutralizing antibodies for the prevention and treatment of COVID-19, with a specific emphasis on cross-reactivity with other two highly pathogenic human coronaviruses, SARS-CoV and MERS-CoV . However, the authors of this article largely disregarded the potential cross-reactive immunity triggered by the prevalence of low pathogenic human coronaviruses (LPH-CoV).
Keywords: SARS-CoV-2; COVID-19; Coronavirus; Immunology.